Sébastien Anguille

Summary

Affiliation: University Hospital Antwerp
Country: Belgium

Publications

  1. pmc Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential
    Sébastien Anguille
    University of Antwerp, Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Antwerp, Belgium
    PLoS ONE 7:e51851. 2012
  2. doi request reprint Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
    S Anguille
    Center for Cell Therapy and Regenerative Medicine U111, Antwerp University Hospital, Edegem, Antwerp, Belgium
    Leukemia 26:2186-96. 2012
  3. doi request reprint [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]
    Sébastien Anguille
    Université d Anvers University of Antwerp, Laboratoire d Hematologie Experimentale, Universiteitsplein 1, 2610 Wilrijk, Anvers, Belgique
    Bull Cancer 99:635-42. 2012
  4. pmc Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
    Sébastien Anguille
    University of Antwerp Faculty of Medicine, Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Universiteitsplein 1, B 2610 Wilrijk Antwerp, Belgium
    J Transl Med 7:109. 2009
  5. pmc Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
    Johan Van den Bergh
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
    Oncotarget 6:44123-33. 2015
  6. doi request reprint Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy
    Evelien L J M Smits
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, D T 431, Wilrijk, Antwerp, 2610, Belgium
    Methods Mol Biol 1393:27-35. 2016
  7. doi request reprint Clinical use of dendritic cells for cancer therapy
    Sébastien Anguille
    Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium Electronic address
    Lancet Oncol 15:e257-67. 2014
  8. pmc Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
    Heleen H Van Acker
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijkstraat 10, 2650, Edegem, Antwerp, Belgium
    J Hematol Oncol 9:101. 2016
  9. pmc Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
    Sébastien Anguille
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
    PLoS ONE 10:e0123340. 2015
  10. doi request reprint Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
    Sébastien Anguille
    Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, Tumor Immunology Group S A, H H V A, H G, E L, V F V T, Z N B, and Faculty of Medicine and Health Sciences, Center for Oncological Research E L S, University of Antwerp, Antwerp, Belgium Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium S A, E L S, Z N B and ANZAC Research Institute, Dendritic Cell Biology and Therapeutics Group, University of Sydney, Sydney, New South Wales, Australia C B, P D F
    Pharmacol Rev 67:731-53. 2015

Collaborators

Detail Information

Publications23

  1. pmc Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential
    Sébastien Anguille
    University of Antwerp, Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Antwerp, Belgium
    PLoS ONE 7:e51851. 2012
    ..The observation that IL-15 DCs have killer DC capacity lends further support to their implementation in DC-based immunotherapy protocols...
  2. doi request reprint Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
    S Anguille
    Center for Cell Therapy and Regenerative Medicine U111, Antwerp University Hospital, Edegem, Antwerp, Belgium
    Leukemia 26:2186-96. 2012
    ..The information provided in this review is intended to guide the rational design of future antigen-specific immunotherapy trials, which will hopefully lead to new antileukemia therapies with more selectivity and higher efficacy...
  3. doi request reprint [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]
    Sébastien Anguille
    Université d Anvers University of Antwerp, Laboratoire d Hematologie Experimentale, Universiteitsplein 1, 2610 Wilrijk, Anvers, Belgique
    Bull Cancer 99:635-42. 2012
    ..Next, we will review the first clinical results obtained with this immunotherapeutic approach in AML patients. Finally, we will briefly reflect on the potential place of DC vaccination in the future therapy of AML...
  4. pmc Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
    Sébastien Anguille
    University of Antwerp Faculty of Medicine, Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Universiteitsplein 1, B 2610 Wilrijk Antwerp, Belgium
    J Transl Med 7:109. 2009
    ..The applicability of these so-called IL-15 DCs has not yet been firmly established. We therefore developed a novel pre-clinical approach for the generation of IL-15 DCs with potent immunostimulatory properties...
  5. pmc Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
    Johan Van den Bergh
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
    Oncotarget 6:44123-33. 2015
    ..In conclusion, we report an attractive approach to improve antitumoral NK-cell activity in DC-based vaccine strategies through the use of IL-15/IL-15Rα mRNA-engineered designer DC. ..
  6. doi request reprint Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy
    Evelien L J M Smits
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, D T 431, Wilrijk, Antwerp, 2610, Belgium
    Methods Mol Biol 1393:27-35. 2016
    ..This in-house-developed transfection method gives rise to presentation of multiple antigen epitopes and can be used for all patients without restriction of human leukocyte antigen (HLA) type...
  7. doi request reprint Clinical use of dendritic cells for cancer therapy
    Sébastien Anguille
    Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium Electronic address
    Lancet Oncol 15:e257-67. 2014
    ....
  8. pmc Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
    Heleen H Van Acker
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijkstraat 10, 2650, Edegem, Antwerp, Belgium
    J Hematol Oncol 9:101. 2016
    ....
  9. pmc Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
    Sébastien Anguille
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
    PLoS ONE 10:e0123340. 2015
    ..The observed lack of membrane-bound IL-15 on "gold-standard" IL-4 DCs and their consequent inability to effectively promote NK cell cytotoxicity may have important implications for the future design of DC-based cancer vaccine studies. ..
  10. doi request reprint Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
    Sébastien Anguille
    Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, Tumor Immunology Group S A, H H V A, H G, E L, V F V T, Z N B, and Faculty of Medicine and Health Sciences, Center for Oncological Research E L S, University of Antwerp, Antwerp, Belgium Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium S A, E L S, Z N B and ANZAC Research Institute, Dendritic Cell Biology and Therapeutics Group, University of Sydney, Sydney, New South Wales, Australia C B, P D F
    Pharmacol Rev 67:731-53. 2015
    ..Given its high suitability for immune interventions, acute myeloid leukemia was chosen here to showcase the latest research trends driving the field of DC-based cancer immunotherapy...
  11. doi request reprint Dendritic cell vaccination in acute myeloid leukemia
    Sébastien Anguille
    University of Antwerp, Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Wilrijk, Antwerp, Belgium
    Cytotherapy 14:647-56. 2012
    ..We discuss the rationale and basic principles of DC-based therapy for AML and review the clinical experience that has been obtained so far with this form of immunotherapy for patients with AML...
  12. doi request reprint mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients
    Ellen Van Gulck
    Department of Biomedical Sciences, Division of Microbiology, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium
    AIDS 26:F1-12. 2012
    ..In an effort to raise protective antiviral immunity, dendritic cell immunotherapy was evaluated in six adults infected with human immunodeficiency virus (HIV)-1 and stable under highly active antiretroviral therapy (HAART)...
  13. pmc Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC
    Eva Lion
    Vaccine and Infectious Disease Institute VAXINFECTIO, Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium
    PLoS ONE 6:e20952. 2011
    ..These data strongly support the use of poly(I:C) as a cancer vaccine component, providing a way to overcome immune evasion by leukemic cells...
  14. pmc Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
    Viggo F Van Tendeloo
    University of Antwerp, Faculty of Medicine, Vaccine and Infectious Disease Institute Vaxinfectio and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp B 2650, Belgium
    Proc Natl Acad Sci U S A 107:13824-9. 2010
    ..These data support the further development of vaccination with WT1 mRNA-loaded dendritic cells as a postremission treatment to prevent full relapse in AML patients...
  15. doi request reprint Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
    Heleen H Van Acker
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Antwerp, Belgium Electronic address
    Pharmacol Ther 158:24-40. 2016
    ..Based on these recent data, the role of bisphosphonates is expected to further expand in the near future outside the field of osteoporosis and to open up new avenues in the treatment of malignancies. ..
  16. pmc The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
    Yannick Willemen
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Oncotarget 7:73960-73970. 2016
    ..Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM...
  17. pmc Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
    Heleen H Van Acker
    Laboratory of Experimental Hematology, Tumor Immunology Group TIGR, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
    Oncotarget . 2017
    ..Moreover, neutralization of CCR5 prior to migration resulted in an important inhibition of γδ T cell and NK cell recruitment by IL-15 DCs. These findings further underscore the strong immunotherapeutic potential of IL-15 DCs...
  18. pmc HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells
    Johan M J Van den Bergh
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
    J Cell Mol Med 18:1372-80. 2014
    ..Our study thus identifies a novel mode of action of the HPV vaccine in boosting innate immunity, including killing of HPV-infected cells by DC and NK cells. ..
  19. doi request reprint Dendritic cell-based cancer gene therapy
    Evelien L J M Smits
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, B 2610 Wilrijk Antwerp, Belgium
    Hum Gene Ther 20:1106-18. 2009
    ..Moreover, a detailed review of the already published trials using gene-modified DCs is presented and future DC-based strategies targeting multiple layers of the complex cellular immune response are highlighted...
  20. ncbi request reprint Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers
    Sébastien Anguille
    University of Antwerp, Vaccine and Infectious Disease Institute Laboratory of Experimental Hematology, Wilrijk Antwerp, Belgium
    Hum Vaccin 7:579-84. 2011
    ..We also discuss the importance of natural killer cells and combination strategies to further improve the outcome of DC-based vaccination in AML patients...
  21. doi request reprint Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions
    Yannick Willemen
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, Antwerp, 2610, Belgium
    Cancer Immunol Immunother 64:831-42. 2015
    ..Altogether, our findings mark IFN-α mRNA-electroporated DCs as potent inducers of both adaptive and innate anti-tumor immunity and pave the way for clinical trial evaluation in cancer patients. ..
  22. pmc Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells
    Amaryllis H Van Craenenbroeck
    1 Department of Nephrology Hypertension, Antwerp University Hospital, Edegem, Belgium 2 Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 3 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 4 Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium 5 Department of Hematology, Antwerp University Hospital, Edegem, Belgium 6 Centre for the Evaluation of Vaccination CEV, Vaccine and Infectious Disease Institute VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 7 Department of Microbiology, Antwerp University Hospital, Edegem, Belgium
    Transplantation 99:120-7. 2015
    ..Infection with human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients...